Clinical Research Directory

Inclusion Criteria: * Adults aged 18-70 years * BMI ≥ 27 kg/m2 - 47.5 kg/m2 and diagnosed with type 2 diabetes by their personal physician (e.g., primary care physician, endocrinologist), or BMI ≥ 30 kg/m2 and have obesity and stable access (i.e., at least a two-month supply) to the medication * Prescribed branded injectable semaglutide or injectable tirzepatide (medication will not be provided as part of the study) * HbA1c will be measured at Pennington Biomedical at baseline (and follow-up), though the baseline HbA1c levels from Pennington Biomedical will not be used for eligibility criteria * Use of other medications (diabetes medications or otherwise) are permitted at the discretion of the Medical Investigator * Enroll and complete baseline assessments prior to starting pharmacotherapy * Able and willing to adhere to all study-related procedures Exclusion Criteria: * Pregnancy or breastfeeding * Taking or planning to take during the trial a medication, vitamin, or mineral supplement that affects vitamin E levels * Previous use of a glucagon-like peptide-1 medication in the last 3 months * Contraindications to glucagon-like peptide-1 medication use or previous adverse reaction/allergy to a glucagon-like peptide-1 receptor agonist medication * Medical, psychological, cognitive, or other conditions that limit the ability to complete study procedure * History of bariatric surgery * Allergic to almonds * Active malignancy, excluding some skin cancers, or undergoing chemotherapy/radiotherapy